ADVA
4.6.2020 09:02:08 CEST | Business Wire | Press release
ADVA (FSE: ADV) today launched the industry’s first ePRC optical cesium atomic clock solution, protecting synchronization networks from costly and dangerous interruptions to satellite signals. The Oscilloquartz OSA 3350 ePRC+ provides unprecedented stability and significantly longer lifetime compared to all other ePRC cesium clocks. It’s also the first cesium clock on the market with built-in SNMP support. This innovation in the design of atomic clocks comes at a critical time when GNSS outages caused by jamming and spoofing attacks are on the rise. Long GNSS disruptions can cause severe network outages and so the OSA 3350 ePRC+ offers vital backup for mission-critical infrastructures that depend on satellite-based timing, such as mobile networks and power utilities. The OSA 3350 ePRC+ also meets the stringent performance demands as well as the cost points needed for mobile networks transitioning to 5G.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200604005036/en/
“Our OSA 3350 ePRC+ is a truly unique achievement and its importance to the industry can’t be overstated. It arrives at a crucial time with operators seeking an efficient way to deliver highly accurate, ultra-stable frequency and phase synchronization with significantly longer lifetime than existing cesium clocks. Now they can mitigate GNSS vulnerabilities by harnessing market-leading holdover performance for the most robust backup available,” said Gil Biran, general manager, Oscilloquartz, ADVA. “Creating a viable commercial optical atomic clock has been a key mission for a long time. By achieving it, we’re making sure that communication service providers never again have to compromise between performance and lifetime. And, with a frequency stability that outperforms current ITU-T ePRC G.811.1 standards, our OSA 3350 ePRC+ provides the safety net needed for 5G networks.”
Featuring an all-digital design, the OSA 3350 ePRC+ leverages optical-pumping techniques. It greatly improves performance by providing an extremely stable frequency source. When used with enhanced primary reference time clocks (ePRTCs), the OSA 3350 ePRC+ delivers holdover for 14 days with an accumulated error of up to 35 nanoseconds. This far exceeds the ITU-T ePRC G.811.1 standard that requires an accumulated error under 70 nanoseconds. The OSA 3350 ePRC+ also delivers optimum stability for over 10 years, which is 100% longer than the lifespan of high-performance magnetic cesium clocks. With a fully modular design, the optical cesium solution features a wide range of telecom synchronization output interfaces and supports modern and secured management capabilities with SNMP. What’s more, the RoHS-compliant device is fully integrated into ADVA’s Ensemble management and control software suite for operational simplicity and ease of use.
“With our OSA 3350 ePRC+, we’re providing a critical component of tomorrow’s network synchronization. For decades, engineers have focused on maximizing the performance of magnetic cesium clocks despite their limitations. Now we’re opening up a new chapter in the history of time and frequency delivery with a technology that optimizes both performance and lifetime,” commented Nir Laufer, senior director, product line management, Oscilloquartz, ADVA. “The incredible stability and accuracy that our OSA 3350 ePRC+ generates will bring essential improvements needed for 5G and other critical infrastructures deriving timing from GNSS. At a time when jamming and spoofing attacks are increasing in frequency and duration, it offers vital backup to satellite-based timing. Our OSA 3350 ePRC+ is also fully integrated into our Ensemble network management software suite with built-in SNMP. It couldn’t be easier to monitor the health of the device and perform software upgrades remotely at the touch of the button.”
Watch this product video for more information: https://youtu.be/8jk4y6kH0Ug .
A supporting application video is available here: https://youtu.be/VarsNZNQB9w .
Further details can also be found in these slides: https://adva.li/osa-3350-slides .
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About Oscilloquartz
Oscilloquartz is a pioneer in time and frequency synchronization. We design, manufacture and deploy end-to-end synchronization systems that ensure the delivery and assurance of highly precise timing information over next-generation packet and legacy networks. As an ADVA company, we're creating new opportunities for tomorrow's networks. For more information, please visit us at www.oscilloquartz.com .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20200604005036/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL30.5.2026 14:00:00 CEST | Press release
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared with R-CHOP alone in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL)Positive trends toward progression-free survival (PFS) benefit with tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypesThe frontMIND data support the submission of global regulatory applications for tafasitamab and lenalidomide added to R-CHOP for previously untreated DLBCLThe data are being presented in an oral session at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet* Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating t
Fortegra Completes Acquisition by DB Insurance29.5.2026 22:30:00 CEST | Press release
The Fortegra Group, Inc. ("Fortegra"), a global specialty insurance company, today announced the completion of its acquisition by DB Insurance Co., Ltd. ("DB"), one of Korea's leading property and casualty insurers. The transaction, announced on September 26, 2025, received all required regulatory and stockholder approvals. Fortegra will operate independently, maintaining its existing leadership team, distribution relationships, and underwriting discipline. Agents, distribution partners, and customers will continue to experience the service excellence that has defined the Fortegra experience. Richard Kahlbaugh, Chairman and CEO of Fortegra, said: "Every company eventually changes ownership. That is the nature of business. The closing of this acquisition is a starting point. As part of DB Insurance, Fortegra is positioned to expand our business geographically, enhance our capabilities and deepen our market presence in the US, Europe, the United Kingdom and Asia. Together, DB Insurance a
SINOVAC Receives Nasdaq Notification Regarding Late Filing of 2025 Annual Report29.5.2026 22:01:00 CEST | Press release
Sinovac Biotech Ltd. (Nasdaq: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that it received a notification letter dated May 20, 2026 (the “Notification Letter”), from Nasdaq Listing Qualifications (“Nasdaq”) stating that as of May 8, 2026, the Company had regained compliance with the periodic filing and interim financial requirements in Nasdaq Listing Rules 5250(c)(1) (the “Periodic Filing Rule”) and 5250(c)(2), as required by the Panel’s decision dated January 21, 2026. As previously disclosed on January 22, 2026, under the Panel’s decision, SINOVAC was required to, on or before May 11, 2026, demonstrate compliance with such Nasdaq Listing Rules by completing filings of its annual report for the year ended December 31, 2024, on Form 20-F and an interim balance sheet and income statement as of the end of its second quarter of 2025 on Form 6-K. The Company timely completed such filings as required by the Panel’s decision.
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
